David Gold, PhD
About David Gold, PhD
David Gold, PhD, serves as the Vice President of Business Development at Sonoma Biotherapeutics, a position he has held since 2022. He has extensive experience in the biopharmaceutical industry, having previously worked in various roles at Regeneron Pharmaceuticals and other notable companies.
Work at Sonoma BioTherapeutics
David Gold serves as the Vice President of Business Development at Sonoma Biotherapeutics, a position he has held since 2022. He is based in the San Francisco Bay Area and is responsible for overseeing business development initiatives within the company. His role involves identifying strategic partnerships and opportunities to advance the company's therapeutic offerings.
Previous Experience at Regeneron Pharmaceuticals
Prior to his current role, Gold worked at Regeneron Pharmaceuticals, Inc. for three years, from 2019 to 2022. He held the position of Senior Director of Strategic Alliances, where he focused on developing and managing strategic partnerships. He also served as Director at Regeneron from 2017 to 2018, contributing to the company's business development efforts.
Career at Adaptive Biotechnologies
Gold was employed at Adaptive Biotechnologies Corp. as Senior Director of Business Development, Therapeutics, from 2015 to 2016. In this role, he was involved in the business development strategies for therapeutic applications, enhancing the company's portfolio in the biotechnology sector.
Experience at Halozyme Therapeutics
Gold's tenure at Halozyme Therapeutics, Inc. spanned several years, where he held multiple positions. From 2012 to 2015, he served as Director of Business Development, and prior to that, he was Associate Director of Alliance Management from 2010 to 2012. His responsibilities included managing partnerships and driving business growth.
Educational Background
David Gold earned his Ph.D. in Biomedical Sciences from UC San Diego, where he studied from 1999 to 2005. He also holds a Bachelor of Science degree in Molecular and Cellular Biology from the University of Washington, which he completed from 1995 to 1999. His educational background laid the foundation for his career in the biotechnology and pharmaceutical industries.